Company intelligence / Profile preview

AiBo Pharmaceutical Research and Development

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Aibo Pharmaceutical is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of innovative therapies for metabolic diseases. The company focuses on multi-target agonists, particularly those targeting the GLP-1, GIP, and glucagon receptors to treat conditions such as type 2 diabetes, obesity, and NASH. Their lead programs include long-acting peptide analogs designed to improve glycemic control and promote weight loss. Aibo Pharmaceutical leverages its expertise in peptide chemistry and metabolic biology to advance a pipeline of next-generation metabolic regulators.

Therapeutic areas: EndocrinologyGastroenterologyMetabolic Disorders
Modalities: Small moleculePeptidesBiologic
Industry: Biotech

Beyond the preview

Go deeper on AiBo Pharmaceutical Research and Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AiBo Pharmaceutical Research and Development.

Explore the full profile